• Je něco špatně v tomto záznamu ?

Cardanol-derived AChE inhibitors: Towards the development of dual binding derivatives for Alzheimer's disease

LF. Lemes, G. de Andrade Ramos, AS. de Oliveira, FM. da Silva, G. de Castro Couto, M. da Silva Boni, MJ. Guimarães, IN. Souza, M. Bartolini, V. Andrisano, PC. do Nascimento Nogueira, ER. Silveira, GD. Brand, O. Soukup, J. Korábečný, NC. Romeiro,...

. 2016 ; 108 (-) : 687-700. [pub] 20151217

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17000685

Cardanol is a phenolic lipid component of cashew nut shell liquid (CNSL), obtained as the byproduct of cashew nut food processing. Being a waste product, it has attracted much attention as a precursor for the production of high-value chemicals, including drugs. On the basis of these findings and in connection with our previous studies on cardanol derivatives as acetylcholinesterase (AChE) inhibitors, we designed a novel series of analogues by including a protonable amino moiety belonging to different systems. Properly addressed docking studies suggested that the proposed structural modifications would allow the new molecules to interact with both the catalytic active site (CAS) and the peripheral anionic site (PAS) of AChE, thus being able to act as dual binding inhibitors. To disclose whether the new molecules showed the desired profile, they were first tested for their cholinesterase inhibitory activity towards EeAChE and eqBuChE. Compound 26, bearing an N-ethyl-N-(2-methoxybenzyl)amine moiety, showed the highest inhibitory activity against EeAChE, with a promising IC50 of 6.6 μM, and a similar inhibition profile of the human isoform (IC50 = 5.7 μM). As another positive feature, most of the derivatives did not show appreciable toxicity against HT-29 cells, up to a concentration of 100 μM, which indicates drug-conform behavior. Also, compound 26 is capable of crossing the blood-brain barrier (BBB), as predicted by a PAMPA-BBB assay. Collectively, the data suggest that the approach to obtain potential anti-Alzheimer drugs from CNSL is worth of further pursuit and development.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000685
003      
CZ-PrNML
005      
20170116095233.0
007      
ta
008      
170103s2016 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejmech.2015.12.024 $2 doi
024    7_
$a 10.1016/j.ejmech.2015.12.024 $2 doi
035    __
$a (PubMed)26735910
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Lemes, Laís Flávia Nunes $u Department of Pharmacy, Health Sciences Faculty, University of Brasília, Campus Universitário Darcy Ribeiro, 70910-900, Brasília, DF, Brazil; LADETER, Catholic University of Brasília, QS 07, Lote 01, EPCT, Águas Claras, 71966-700, Brasília, DF, Brazil.
245    10
$a Cardanol-derived AChE inhibitors: Towards the development of dual binding derivatives for Alzheimer's disease / $c LF. Lemes, G. de Andrade Ramos, AS. de Oliveira, FM. da Silva, G. de Castro Couto, M. da Silva Boni, MJ. Guimarães, IN. Souza, M. Bartolini, V. Andrisano, PC. do Nascimento Nogueira, ER. Silveira, GD. Brand, O. Soukup, J. Korábečný, NC. Romeiro, NG. Castro, ML. Bolognesi, LA. Romeiro,
520    9_
$a Cardanol is a phenolic lipid component of cashew nut shell liquid (CNSL), obtained as the byproduct of cashew nut food processing. Being a waste product, it has attracted much attention as a precursor for the production of high-value chemicals, including drugs. On the basis of these findings and in connection with our previous studies on cardanol derivatives as acetylcholinesterase (AChE) inhibitors, we designed a novel series of analogues by including a protonable amino moiety belonging to different systems. Properly addressed docking studies suggested that the proposed structural modifications would allow the new molecules to interact with both the catalytic active site (CAS) and the peripheral anionic site (PAS) of AChE, thus being able to act as dual binding inhibitors. To disclose whether the new molecules showed the desired profile, they were first tested for their cholinesterase inhibitory activity towards EeAChE and eqBuChE. Compound 26, bearing an N-ethyl-N-(2-methoxybenzyl)amine moiety, showed the highest inhibitory activity against EeAChE, with a promising IC50 of 6.6 μM, and a similar inhibition profile of the human isoform (IC50 = 5.7 μM). As another positive feature, most of the derivatives did not show appreciable toxicity against HT-29 cells, up to a concentration of 100 μM, which indicates drug-conform behavior. Also, compound 26 is capable of crossing the blood-brain barrier (BBB), as predicted by a PAMPA-BBB assay. Collectively, the data suggest that the approach to obtain potential anti-Alzheimer drugs from CNSL is worth of further pursuit and development.
650    _2
$a Alzheimerova nemoc $x farmakoterapie $x enzymologie $7 D000544
650    _2
$a vazebná místa $x účinky léků $7 D001665
650    _2
$a cholinesterasové inhibitory $x chemická syntéza $x chemie $x farmakologie $7 D002800
650    _2
$a cholinesterasy $x metabolismus $7 D002802
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a buňky HT-29 $7 D019073
650    _2
$a lidé $7 D006801
650    _2
$a molekulární struktura $7 D015394
650    _2
$a fenoly $x chemická syntéza $x chemie $x farmakologie $7 D010636
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a de Andrade Ramos, Giselle $u Department of Pharmacy, Health Sciences Faculty, University of Brasília, Campus Universitário Darcy Ribeiro, 70910-900, Brasília, DF, Brazil; LADETER, Catholic University of Brasília, QS 07, Lote 01, EPCT, Águas Claras, 71966-700, Brasília, DF, Brazil.
700    1_
$a de Oliveira, Andressa Souza $u Department of Pharmacy, Health Sciences Faculty, University of Brasília, Campus Universitário Darcy Ribeiro, 70910-900, Brasília, DF, Brazil; LADETER, Catholic University of Brasília, QS 07, Lote 01, EPCT, Águas Claras, 71966-700, Brasília, DF, Brazil.
700    1_
$a da Silva, Fernanda Motta R $u Biomedical Sciences Institute (ICB), Federal University of Rio de Janeiro, 21941-902, Rio de Janeiro, RJ, Brazil.
700    1_
$a de Castro Couto, Gina $u Biomedical Sciences Institute (ICB), Federal University of Rio de Janeiro, 21941-902, Rio de Janeiro, RJ, Brazil.
700    1_
$a da Silva Boni, Marina $u Biomedical Sciences Institute (ICB), Federal University of Rio de Janeiro, 21941-902, Rio de Janeiro, RJ, Brazil.
700    1_
$a Guimarães, Marcos Jorge R $u Biomedical Sciences Institute (ICB), Federal University of Rio de Janeiro, 21941-902, Rio de Janeiro, RJ, Brazil.
700    1_
$a Souza, Isis Nem O $u Biomedical Sciences Institute (ICB), Federal University of Rio de Janeiro, 21941-902, Rio de Janeiro, RJ, Brazil.
700    1_
$a Bartolini, Manuela $u Department of Pharmacy and Biotechnology, University of Bologna, Via Belmeloro 6, 40126, Bologna, Italy.
700    1_
$a Andrisano, Vincenza $u Department for Life Quality Studies, University of Bologna, Corso D'Augusto 237, 47921, Rimini, Italy. $7 gn_A_00006674
700    1_
$a do Nascimento Nogueira, Patrícia Coelho $u CENAUREMN, Department of Organic and Inorganic Chemistry, Federal University of Ceará, 60021-970, Fortaleza, CE, Brazil.
700    1_
$a Silveira, Edilberto Rocha $u CENAUREMN, Department of Organic and Inorganic Chemistry, Federal University of Ceará, 60021-970, Fortaleza, CE, Brazil.
700    1_
$a Brand, Guilherme D $u Chemistry Institute, University of Brasília, Campus Universitário Darcy Ribeiro, 70910-900, Brasília, DF, Brazil.
700    1_
$a Soukup, Ondřej $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; National Institute of Mental Health, Topolová 748, 250 67, Klecany, Czech Republic.
700    1_
$a Korábečný, Jan $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; National Institute of Mental Health, Topolová 748, 250 67, Klecany, Czech Republic.
700    1_
$a Romeiro, Nelilma C $u LICC - Laboratório Integrado de Computação Científica, NUPEM, Federal University of Rio de Janeiro, 27901-000, Macaé, RJ, Brazil.
700    1_
$a Castro, Newton G $u Biomedical Sciences Institute (ICB), Federal University of Rio de Janeiro, 21941-902, Rio de Janeiro, RJ, Brazil.
700    1_
$a Bolognesi, Maria Laura $u Department of Pharmacy and Biotechnology, University of Bologna, Via Belmeloro 6, 40126, Bologna, Italy. Electronic address: marialaura.bolognesi@unibo.it.
700    1_
$a Romeiro, Luiz Antonio Soares $u Department of Pharmacy, Health Sciences Faculty, University of Brasília, Campus Universitário Darcy Ribeiro, 70910-900, Brasília, DF, Brazil; LADETER, Catholic University of Brasília, QS 07, Lote 01, EPCT, Águas Claras, 71966-700, Brasília, DF, Brazil. Electronic address: luizromeiro@unb.br.
773    0_
$w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 108, č. - (2016), s. 687-700
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26735910 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170116095337 $b ABA008
999    __
$a ok $b bmc $g 1179825 $s 961252
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 108 $c - $d 687-700 $e 20151217 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Možnosti archivace